Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
NCT05025605
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
- Schizo-Affective Disorder
- Schizophreniform; Schizophrenic
- Bipolar Disorder I
- Bipolar Disorder II
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 10 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- BioXcel Therapeutics Inc
- Last updated on ClinicalTrials.gov
- August 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- BioXcel Clinical Research Site · Anaheim, CA
Florida · 1
- Bioxcel Clinical Research Site · Hialeah, FL
Georgia · 1
- Bioxcel Clinical Research Site · Decatur, GA
Texas · 1
- BioXcel Clinical Research Site · DeSoto, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.